ArticleTranslational cancer research2026
RNAscope-based HER2 mRNA detection shows high concordance with fluorescence
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human epidermal growth factor receptor 2 (HER2) status is critical for guiding targeted therapy in invasive breast cancer (BC). Immunohistochemistry (IHC) is routinely used for HER2 screening, but equivocal (IHC 2+) cases require confirmatory testing. RNAscope is an emerging RNA Methods: In this retrospective study, 104 IDC cases from January 2020 to January 2024 were reviewed. Thirty-five cases with IHC 2+ scores were randomly selected. Each case underwent RNAscope and fluorescence in situ hybridization (FISH) for HER2. Concordance between RNAscope and FISH results was evaluated using Cohen's kappa statistic. Next-generation sequencing (NGS) was performed on discordant cases to confirm HER2 gene status. Results: RNAscope and FISH results were concordant in 85.7% (30/35) of IHC 2+ cases [κ=0.678, 95% confidence interval (CI): 0.425-0.872], indicating substantial agreement. RNAscope detected HER2 positivity in all 12 FISH-positive cases (100% agreement) and in 5 of 23 FISH-negative cases, identifying additional positive cases. Among the 5 discordant cases, NGS confirmed HER2 amplification or overexpression in 4 (80%) of the RNAscope-positive/FISH-negative cases. These findings suggest that RNAscope may detect HER2-positive cases missed by FISH. Conclusions: RNAscope shows high agreement with FISH in determining HER2 status in IHC 2+ IDC. RNAscope may serve as an effective adjunct to current HER2 testing, offering a sensitive alternative for ambiguous cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.